BIOGEN INC.
BIIB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BIIB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BIIB
Biogen Inc. (BIIB) is a biotechnology company focused on neurology, immunology, and rare diseases, with a late-stage pipeline and growth products including SKYCLARYS, QALSODY, ZURZUVAE, and LEQEMBI. As of 2026-03-31, the company reported cash & equivalents of $3,382.7M, total revenue of $2,477.8M, net income of $319.5M, and total debt of $12,577.0M [sec].
Key risk: Pipeline execution risk
BioSniper Score
Based on 6 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 14 pipeline candidates · 48 clinical trials · 17 catalysts · 7 FDA decisions for BIOGEN INC..
Biogen Inc. (BIIB) is a biotechnology company focused on neurology, immunology, and rare diseases, with a late-stage pipeline and growth products including SKYCLARYS, QALSODY, ZURZUVAE, and LEQEMBI. As of 2026-03-31, the company reported cash & equivalents of $3,382.7M, total revenue of $2,477.8M, net income of $319.5M, and total debt of $12,577.0M [sec].
- Biogen increased growth product revenue by 19% year-over-year to $3.3 billion in 2025, led by SKYCLARYS, QALSODY, ZURZUVAE, and VUMERITY [sec · filed 2026-04-28].
- The company has a high-conviction late-stage pipeline in neurology, immunology, and rare disease, with key milestones including regulatory approvals for LEQEMBI, SKYCLARYS, and QALSODY across major global markets [sec · filed 2026-04-28].
- As of 2026-03-31, Biogen had cash & equivalents of $3,382.7M, total revenue of $2,477.8M, net income of $319.5M, and total debt of $12,577.0M [sec].
- Biogen entered strategic collaborations including a partnership with City to develop RNAi therapies, licensing an oral C5aR1 antagonist from Vanqua, and acquiring Alcyone to advance ASO delivery [sec · filed 2026-04-28].
- The company achieved targeted productivity improvements and exceeded top talent retention goals, while establishing operational manufacturing expansion plans [sec · filed 2026-04-28].
What works
- Biogen's growth product revenue increased 19% year-over-year to $3.3 billion in 2025, indicating strong commercial execution for newer products like SKYCLARYS, QALSODY, and ZURZUVAE [sec · filed 2026-04-28].
- The company has a high-conviction late-stage pipeline with multiple Phase 3 trials ongoing, including felzartamab for IgA nephropathy and higher-dose nusinersen for spinal muscular atrophy, providing potential for future growth [sec · filed 2026-04-28].
- Biogen has established strategic collaborations and acquisitions (e.g., RNAi partnership with City, Vanqua license, Alcyone acquisition) to expand its pipeline and technology platforms [sec · filed 2026-04-28].
What to weigh
- Non-GAAP diluted earnings per share declined in 2025 compared to 2024, reflecting expected total revenue decline and planned investments in pipeline and launches [sec · filed 2026-04-28].
- The company faces significant debt of $12,577.0M as of 2026-03-31, which may constrain financial flexibility [sec].
- Biogen's legacy product performance is under pressure from generic competition, and the company is reliant on growth products to replace mature franchises [sec · filed 2026-04-28].
From the filings
Quoted directly from source documents.
Growth product revenue increased 19% year-over-year in 2025
“The Company increased growth product revenue by 19% year-over-year to $3.3 billion, led by SKYCLARYS, QALSODY, ZURZUVAE, VUMERITY”
SEC filings · April 28, 2026
Biogen is focused on neurology, immunology, and rare disease pipeline
“a high-conviction late-stage pipeline with the potential to drive both meaningful innovation and sustained growth. We made notable progress on this strategy in 2025, where execution on commercialization of our growth products and a sharpened development pipeline focused on neurology, immunology, and rare disease are laying a strong foundation for Biogen's future.”
SEC filings · April 28, 2026
Catalyst timeline
- 2027-06-01 · Phase3_Topline · felzartamab — Phase 3 Topline: A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy an — Topline data for felzartamab in IgA nephropathy; will inform potential regulatory submission.
- 2027-09-24 · Phase3_Topline — Phase 3 Topline: A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrop — Topline data for higher-dose nusinersen in SMA; could expand SPINRAZA franchise.
- 2027-12-14 · Phase3_Topline — Phase 3 Topline: A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Mu — Topline data from a seamless Phase 2/3 study; specific indication not fully disclosed.
- 2029-06-05 · Phase3_Topline · felzartamab — Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Neph — Second Phase 3 topline for felzartamab in IgA nephropathy; may support broader label.
- 2029-06-30 · Phase3_Topline — Phase 3 Topline: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phas — Topline data from an 18-month study with open-label extension; likely for a rare disease candidate.
- 2029-11-22 · Phase3_Topline — Phase 3 Topline: A Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omavelox — Topline data for omaveloxolone; potential Friedreich's ataxia treatment.
- 2029-12-11 · Phase3_Topline — Phase 3 Topline: A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Saf — Long-term extension study topline; assesses safety and durability of an existing candidate.
- 2030-03-29 · Phase3_Topline — Phase 3 Topline: A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous — Long-term extension study topline; evaluates continuous dosing of a candidate.
Risks & what to watch (4)›
Key risks
- Pipeline execution risk — Development programs are subject to high risk and investment; status, timing, and scope may change [sec_mda · as of 2026-02-06].
- Generic competition for legacy products — Biogen drove legacy product performance despite generic competition, indicating pressure on mature franchises [sec · filed 2026-04-28].
- High debt burden — Total debt of $12,577.0M as of 2026-03-31 may limit financial flexibility and increase interest costs [sec].
- Dependence on growth products — Growth product revenue is weighted 2.5 times more than total revenue, with ambitious assumptions for launches [sec · filed 2026-04-28].
What to watch
- Phase 3 topline results for felzartamab in IgA nephropathy expected in 2027 and 2029 [catalyst timeline].
- Phase 3 topline results for higher-dose nusinersen (BIIB058) in spinal muscular atrophy expected in 2027 [catalyst timeline].
- Phase 3 topline results for omaveloxolone in an 18-month study expected in 2029 [catalyst timeline].
- Execution of strategic collaborations (RNAi, Vanqua, Alcyone) and their impact on pipeline advancement [sec · filed 2026-04-28].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BIOGEN INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIOGEN INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $646M · Net income $320M · Debt/OCF 3.6×
Lead: Approved
14 candidates
17 upcoming, next in ~275d
0 buys · 2 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,000
Total value held
$25.65B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 19,074,834 | $3.50B |
| blackrock, inc. | 15,974,601 | $2.93B |
| primecap management co/ca/ | 14,757,607 | $2.71B |
| fmr llc | 12,807,541 | $2.35B |
| state street corp | 7,167,922 | $1.31B |
| vanguard portfolio management llc | 6,531,727 | $1.20B |
| geode capital management, llc | 4,342,602 | $793.4M |
| wellington management group llp | 2,961,641 | $543.0M |
| morgan stanley | 2,170,940 | $398.0M |
| aqr capital management llc | 1,923,557 | $346.2M |
Showing top 10 of 1,000 institutional holders of BIOGEN INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.4%
- Days to cover
- 3.2
- Shares short
- 4,475,470
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BIIB short interestGovernance
Frequently asked questions
What is the AI investment thesis for BIOGEN INC.?
Biogen Inc. (BIIB) is a biotechnology company focused on neurology, immunology, and rare diseases, with a late-stage pipeline and growth products including SKYCLARYS, QALSODY, ZURZUVAE, and LEQEMBI. As of 2026-03-31, the company reported cash & equivalents of $3,382.7M, total revenue of $2,477.8M, net income of $319.5M, and total debt of $12,577.0M [sec].
What is BIOGEN INC.'s lead drug candidate?
BIOGEN INC.'s most advanced tracked candidate is BIIB080 (Phase 3) for Healthy Volunteer.
What is BIOGEN INC.'s next catalyst?
BIOGEN INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy an" — expected June 1, 2027.
Who is the CEO of BIOGEN INC.?
Mr. Christopher A. Viehbacher is the chief executive officer of BIOGEN INC. (BIIB).
Where is BIOGEN INC. headquartered?
BIOGEN INC. (BIIB) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.